21.01.2020 14:24:11
|
Seattle Genetics Achieves Milestone On EU Approval Of Roche's Polivy
(RTTNews) - Seattle Genetics Inc. (SGEN) said that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy.
Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' technology. It was developed and is commercialized by Roche/Genentech.
Polivy was approved in combination with bendamustine plus MabThera for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant.
Polivy was granted PRIME designation by the European Medicines Agency for the treatment of people with R/R DLBCL in 2017.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Seattle Genetics Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |